Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy.

Wilson CS, Butch AW, Lai R, Medeiros LJ, Sawyer JR, Barlogie B, McCourty A, Kelly K, Brynes RK.

Br J Haematol. 2001 Mar;112(3):776-82.

PMID:
11260083
2.

The (11;14)(q13;q32) translocation in multiple myeloma. A morphologic and immunohistochemical study.

Hoyer JD, Hanson CA, Fonseca R, Greipp PR, Dewald GW, Kurtin PJ.

Am J Clin Pathol. 2000 Jun;113(6):831-7.

PMID:
10874884
3.

Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).

Guglielmelli T, Giugliano E, Cappia S, Papotti M, Saglio G.

Cancer Genet Cytogenet. 2007 Feb;173(1):51-6.

PMID:
17284370
4.

Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1.

Yata K, Sadahira Y, Otsuki T, Sakaguchi H, Isozaki Y, Uno M, Kurebayashi J, Fujii T, Eda S, Ueki A, Yawata Y, Yamada O, Sugihara T.

Br J Haematol. 2001 Sep;114(3):591-9. Erratum in: Br J Haematol 2002 Mar;116(3):730.

PMID:
11552984
5.

Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).

Pruneri G, Fabris S, Baldini L, Carboni N, Zagano S, Colombi MA, Ciceri G, Lombardi L, Rocchi M, Buffa R, Maiolo AT, Neri A.

Am J Pathol. 2000 May;156(5):1505-13.

6.

Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.

Katayama Y, Sakai A, Okikawa Y, Oue N, Asaoku H, Sasaki A, Imanaka F, Tsujimoto T, Takimoto Y, Masuda R, Nakaju N, Otsuki T, Yasui W, Kimura A.

Int J Oncol. 2004 Sep;25(3):579-95.

PMID:
15289859
7.

Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels.

Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I, Tomer R, Hofler H, Schuuring E, Kluin PM, Fend F, Quintanilla-Martinez L.

Blood. 2004 Aug 15;104(4):1120-6. Epub 2004 Apr 13.

8.

Immunohistochemical analysis of cyclin D1 and p53 in multiple myeloma: relationship to proliferative activity and prognostic significance.

Markovic O, Marisavljevic D, Cemerikic V, Suvajdzic N, Milic N, Colovic M.

Med Oncol. 2004;21(1):73-80.

PMID:
15034217
9.

Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.

Nagasaka T, Lai R, Medeiros LJ, Brynes RK, McCourty A, Harada T, Saddik M.

Am J Dermatopathol. 1999 Apr;21(2):115-20.

PMID:
10218669
10.

E2F-1: a proliferative marker of breast neoplasia.

Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, Klein-Szanto AJ.

Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):395-401.

11.

A new multiple myeloma cell line, MEF-1, possesses cyclin D1 overexpression and the p53 mutation.

Yufu Y, Goto T, Choi I, Uike N, Kozuru M, Ohshima K, Taniguchi T, Motokura T, Yatabe Y, Nakamura S.

Cancer. 1999 Apr 15;85(8):1750-7.

PMID:
10223569
12.

Alterations of cell cycle regulators affecting the RB pathway in nonfamilial retinoblastoma.

Orjuela M, Orlow I, Dudas M, Ponce-Castañeda MV, Ridaura C, Leal C, Salazar A, Abramson D, Gerald W, Cordon-Cardo C.

Hum Pathol. 2001 May;32(5):537-44.

PMID:
11381373
13.

Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections.

Specht K, Kremer M, Müller U, Dirnhofer S, Rosemann M, Höfler H, Quintanilla-Martinez L, Fend F.

Clin Cancer Res. 2002 Sep;8(9):2902-11.

14.

Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity.

Lai R, Medeiros LJ, Wilson CS, Sun NC, Koo C, McCourty A, Brynes RK.

Mod Pathol. 1998 Jul;11(7):642-7.

PMID:
9688185
15.

Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32).

Kobayashi H, Saito H, Kitano K, Kiyosawa K, Gaun S, Aoki K, Narita A, Watanabe M, Uchimaru K, Motokura T.

Acta Haematol. 1995;94(4):199-203.

PMID:
8610478
16.

Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions.

Saiz AD, Olvera M, Rezk S, Florentine BA, McCourty A, Brynes RK.

J Pathol. 2002 Oct;198(2):157-62.

17.

Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.

Athanasiou E, Kaloutsi V, Kotoula V, Hytiroglou P, Kostopoulos I, Zervas C, Kalogiannidis P, Fassas A, Christakis JI, Papadimitriou CS.

Am J Clin Pathol. 2001 Oct;116(4):535-42.

PMID:
11601138
18.

Cyclin D1 positive multiple myeloma: predominance of the short, 3'UTR-deficient transcript is associated with high cyclin D1 mRNA levels in cases with t(11;14) translocation, but does not correlate with proliferation rate or genomic deletions.

Slotta-Huspenina J, Koch I, Richter M, Bink K, Kremer M, Specht K, Krugmann J, Quintanilla-Martinez L, Fend F.

Leuk Res. 2008 Jan;32(1):79-88. Epub 2007 Jul 16.

PMID:
17629555
19.

Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck.

Akervall J, Borg A, Dictor M, Jin C, Jin Y, Tanner M, Isola J, Mertens F, Wennerberg J.

Int J Oncol. 2002 Jan;20(1):45-52.

PMID:
11743641
20.

Horizontal basal cell proliferation in the olfactory epithelium of transforming growth factor-alpha transgenic mice.

Getchell TV, Narla RK, Little S, Hyde JF, Getchell ML.

Cell Tissue Res. 2000 Feb;299(2):185-92.

PMID:
10741459

Supplemental Content

Support Center